IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Login to save this paper or follow this series

Nuove politiche per l'innovazione nel settore delle scienze della vita

  • Laura Magazzini

    ()

    (Department of Economics, University of Verona)

  • Fabio Pammolli

    ()

    (IMT Lucca Institute for Advanced Studies and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    ()

    (IMT Lucca Institute for Advanced Studies and and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

Le malattie rare, che colpiscono pochi pazienti nei Paesi sviluppati nonché quelle dimenticate del Terzo Mondo, rappresentano la nuova frontiera della ricerca biomedica, una delle sfide più pressanti alla globalizzazione dei diritti dei malati, e anche un'importante occasione di crescita economica e di sviluppo industriale per l'Italia. Lo afferma uno studio del Cerm elaborato da Fabio Pammolli, il direttore del centro studi, Massimo Riccaboni e Laura Magazzini. La nostra cultura troppo spesso ci porta a scorrere le classifiche dall'alto: i libri più letti, i prodotti più venduti, i siti più vistitati, e sempre si ignora la coda della classifica pensando che sia popolata da pochi e quindi trascurabili casi. Ancor più grave è che siano ricercatori e imprenditori ad attenersi a questa regola. Il Cerm stima che 5 nuove malattie rare sono scoperte e descritte ogni settimana, e che ad oggi se ne conoscono oltre 9.000 in tutto il mondo. Sebbene considerate singolarmente le malattie rare in Europa colpiscano meno di 5 individui su 10.000, nel loro complesso esse riguardano 30 milioni di Europei e 3 milioni di Italiani, con un'incidenza sul 3-4 percento sulle nascite. Le malattie rare colpiscono per il 70 percento bambini, che nel 30 percento dei casi muoiono prima del compimento del quinto anno di età. Saper leggere le classifiche dal fondo, in un Paese in cui piccola scala e solidarietà sanno convivere, può rivelarsi una virtù, soprattutto nelle fasi di crisi economica. Occorre sostenere la ricerca che fa impresa lontano dai riflettori, per la lunga coda dei bisogni rari.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://www.cermlab.it/wp-content/uploads/cerm/wp/wpcerm-2009-03.pdf
File Function: First version, 2009
Download Restriction: no

Paper provided by Competitività Regole Mecati (CERM) in its series Working Papers with number 03-2009.

as
in new window

Length: 263 pages
Date of creation: Mar 2009
Date of revision:
Handle: RePEc:ern:wpaper:03-2009
Contact details of provider: Postal: Via Fiorentina, 1, 53100 Siena
Phone: +39 3488120691
Web page: http://www.cermlab.it/Email:


More information through EDIRC

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

as in new window
  1. Needham, Douglas, 1975. "Market Structure and Firms' R & D Behavior," Journal of Industrial Economics, Wiley Blackwell, vol. 23(4), pages 241-55, June.
  2. Amy Finkelstein, 2003. "Health Policy and Technological Change: Evidence from the Vaccine Industry," NBER Working Papers 9460, National Bureau of Economic Research, Inc.
  3. Jaffe, Adam B, 1988. "Demand and Supply Influences in R&D Intensity and Productivity Growth," The Review of Economics and Statistics, MIT Press, vol. 70(3), pages 431-37, August.
  4. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni & Maria Alessandra Rossi, 2009. "Patent disclosure and R&D competition in pharmaceuticals," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 18(5), pages 467-486.
  5. Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
  6. Orsenigo, L. & Pammolli, F. & Riccaboni, Massimo, 2001. "Technological change and network dynamics: Lessons from the pharmaceutical industry," Research Policy, Elsevier, vol. 30(3), pages 485-508, March.
  7. Yamasaki, Kazuko & Matia, Kaushik & Buldyrev, Sergey V. & Fu, Dongfeng & Pammolli, Fabio & Riccaboni, Massimo & Stanley, H. Eugene, 2004. "Preferential attachment and growth dynamics in complex systems," MPRA Paper 15908, University Library of Munich, Germany, revised 06 Feb 2006.
  8. Kenneth Arrow, 1962. "Economic Welfare and the Allocation of Resources for Invention," NBER Chapters, in: The Rate and Direction of Inventive Activity: Economic and Social Factors, pages 609-626 National Bureau of Economic Research, Inc.
  9. Moors, Ellen H.M. & Faber, Jan, 2007. "Orphan drugs: Unmet societal need for non-profitable privately supplied new products," Research Policy, Elsevier, vol. 36(3), pages 336-354, April.
  10. Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005. "Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances," Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
  11. Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.
  12. Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
  13. Frank R. Lichtenberg & Tomas J. Philipson, 2002. "The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 643-672.
  14. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
  15. Giebe, Thomas & Grebe, Tim & Wolfstetter, Elmar, 2006. "How to allocate R&D (and other) subsidies: An experimentally tested policy recommendation," Research Policy, Elsevier, vol. 35(9), pages 1261-1272, November.
  16. Lerner, Josh, 1995. "Patenting in the Shadow of Competitors," Journal of Law and Economics, University of Chicago Press, vol. 38(2), pages 463-95, October.
  17. Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
  18. Richard R. Nelson, 1959. "The Simple Economics of Basic Scientific Research," Journal of Political Economy, University of Chicago Press, vol. 67, pages 297.
Full references (including those not matched with items on IDEAS)

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:03-2009. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ()

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.